MPT (NYSE: MPT) grants finance SVP 75,000 time and performance shares

Q: How do the 50,000 MPT shares granted to Lambert vest?

The 50,000-share award vests in quarterly installments. These shares vest ratably at the beginning of each of the 12 calendar quarters starting April 1, 2026, creating a three-year vesting schedule tied to continued service over that period.

Q: What performance conditions apply to Lambert’s 25,000 MPT share award?

The 25,000-share award depends on debt and revenue targets. Shares will be earned based on meeting specific thresholds for overall debt reduction and cash revenue growth from January 1, 2026 through December 31, 2028, as defined by the compensation committee.

Q: Over what period can Lambert earn the performance-based MPT shares?

The performance award covers the 2026–2028 period. Performance is measured from January 1, 2026 through December 31, 2028, with the opportunity to earn up to one third of the award based on 2026 performance against the specified metrics.

Q: Are Lambert’s MPT stock awards open-market purchases or compensation grants?

Both transactions are compensation-related stock grants. They are classified as acquisitions under transaction code A, indicating grants or awards at a price of $0.0000 per share, rather than open-market purchases or sales by the executive.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MEDICAL PROPERTIES TRUST INC senior vice president of finance and treasurer Charles R. Lambert reported stock-based compensation awards. He acquired 50,000 shares of common stock at no cost and then an additional 25,000 shares, bringing his direct holdings to 392,401 shares after the second grant.

The 50,000-share award vests in equal installments at the beginning of each of the 12 calendar quarters starting on April 1, 2026. The 25,000-share award is performance-based and will be earned over the period from January 1, 2026 through December 31, 2028, depending on specific thresholds for overall debt reduction and cash revenue growth set by the compensation committee, with up to one third tied to 2026 performance.

Insider Trade Summary

Net Buyer: 75,000 shares

Net Buy 2 txns

Insider LAMBERT CHARLES R

Role SVP of Finance and Treasurer

Type	Security	Shares	Price	Value
Grant/Award	Common stock, par value $0.001	50,000	$0.00	$0.00
Grant/Award	Common stock, par value $0.001	25,000	$0.00	$0.00

Holdings After Transaction: Common stock, par value $0.001 — 392,401 shares (Direct)

Footnotes (2)

F1. Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2026.
F2. Shares will be earned based on the achievement of specific performance thresholds pertaining to the Company's reduction of overall debt and cash revenue growth, as defined and set by our compensation committee, over the period from January 1, 2026 through December 31, 2028, with the opportunity to earn up to one third of the award for 2026 performance against the specified measures. The actual number of shares to be issued will vary depending upon the achievement of these specific performance thresholds.

FAQ

What insider transactions did MPT executive Charles R. Lambert report?

Charles R. Lambert reported two stock awards totaling 75,000 shares. He received 50,000 shares and an additional 25,000 shares of MEDICAL PROPERTIES TRUST INC common stock as equity compensation grants, both at no cost, increasing his direct holdings to 392,401 shares.

How do the 50,000 MPT shares granted to Lambert vest?

The 50,000-share award vests in quarterly installments. These shares vest ratably at the beginning of each of the 12 calendar quarters starting April 1, 2026, creating a three-year vesting schedule tied to continued service over that period.

Over what period can Lambert earn the performance-based MPT shares?

The performance award covers the 2026–2028 period. Performance is measured from January 1, 2026 through December 31, 2028, with the opportunity to earn up to one third of the award based on 2026 performance against the specified metrics.

Are Lambert’s MPT stock awards open-market purchases or compensation grants?

Both transactions are compensation-related stock grants. They are classified as acquisitions under transaction code A, indicating grants or awards at a price of $0.0000 per share, rather than open-market purchases or sales by the executive.

How many MPT shares does Lambert hold after these grants?

Lambert holds 392,401 MPT common shares directly after the grants. His holdings increased as a result of the 50,000-share time-based vesting award and the 25,000-share performance-based award reported in this Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/19/2026 - 07:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAMBERT CHARLES R

(Last)

(First)

(Middle)

10500 LIBERTY PARKWAY

(Street)

BIRMINGHAM

ALABAMA

35242

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MEDICAL PROPERTIES TRUST INC [ MPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP of Finance and Treasurer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, par value $0.001	03/18/2026		A		50,000⁽¹⁾	A	$0	367,401	D
Common stock, par value $0.001	03/18/2026		A		25,000⁽²⁾	A	$0	392,401	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares vest ratably at the beginning of each of the 12 calendar quarters beginning April 1, 2026.

2. Shares will be earned based on the achievement of specific performance thresholds pertaining to the Company's reduction of overall debt and cash revenue growth, as defined and set by our compensation committee, over the period from January 1, 2026 through December 31, 2028, with the opportunity to earn up to one third of the award for 2026 performance against the specified measures. The actual number of shares to be issued will vary depending upon the achievement of these specific performance thresholds.

	W. Zachary Riddle, by power of attorney	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR